Dr. Sonia Guedan is an expert in gene and cell therapy for the treatment of cancer. During her early career, she developed of an oncolytic virus able to degrade the extracellular matrix of solid tumors. Then, she conducted her postdoctoral training at the University of Pennsylvania, in the laboratory that developed the first FDA-approved CAR-T cell therapy. There, she generated novel CAR-T cell therapies with enhanced therapeutic potential and provided the rationale to test them in human clinical trials. She is currently leading a research program at IDIBAPS (Barcelona, Spain) to develop next generation CAR-T cell therapies. Her group focuses on understanding the challenges that CAR-T cells face in solid tumors and hematologic malignancies and developing novel strategies to overcome them.